Added to YB: 2024-07-04
Pitch date: 2024-07-03
ARDX [bullish]
Ardelyx, Inc.
+17.42%
current return
Author Info
No bio for this author
Company Info
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$5.28
Price Target
15.00 (+142%)
Dividend
N/A
EV/EBITDA
-43.88
P/E
-24.60
EV/Sales
3.53
Sector
Biotechnology
Category
special_situation
Ardelyx, Inc. (ARDX): Buying Opportunity Amid Medicare Revenue Risks, Strong Buy Reiterated
ARDX: Strong Buy, $15 PT (-$1). No Xphozah TDAPA application; Medicare coverage lost Jan 2025 unless Kidney Patient Act passes. 30% drop to $5.28 = 2X 2029 Ibsrela sales. Opportunity to buy weakness. $748M US peak sales est. Model: 50% PoS for 2025-26 Medicare sales (63% of market), removed 2027-28. Risks: Medicare revenue loss, commercial access erosion.
Read full article (1 min)